1 Hayashi K, "Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population" 12 : 106-110, 2005
2 Tahata Y, "The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin" 51 : 252-259, 2016
3 Kumada H, "Telaprevir with peginterferon and ribavirin for treatment- naive patients chronically infected with HCV of genotype 1 in Japan" 56 : 78-84, 2012
4 Jacobson IM, "Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial" 384 : 403-413, 2014
5 Manns M, "Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial" 384 : 414-426, 2014
6 Hayashi N, "Simeprevir with peginterferon/ ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial" 61 : 219-227, 2014
7 Reddy KR, "Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial" 15 : 27-35, 2015
8 Bota S, "Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review" 5 : 120-126, 2013
9 Roomer R, "Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C" 52 : 1225-1231, 2010
10 Tamai H, "Prediction of sustained virological response to telaprevir-based triple therapy using viral response within 2 weeks" 2014 : 748935-, 2014
1 Hayashi K, "Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population" 12 : 106-110, 2005
2 Tahata Y, "The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin" 51 : 252-259, 2016
3 Kumada H, "Telaprevir with peginterferon and ribavirin for treatment- naive patients chronically infected with HCV of genotype 1 in Japan" 56 : 78-84, 2012
4 Jacobson IM, "Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial" 384 : 403-413, 2014
5 Manns M, "Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial" 384 : 414-426, 2014
6 Hayashi N, "Simeprevir with peginterferon/ ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial" 61 : 219-227, 2014
7 Reddy KR, "Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial" 15 : 27-35, 2015
8 Bota S, "Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review" 5 : 120-126, 2013
9 Roomer R, "Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C" 52 : 1225-1231, 2010
10 Tamai H, "Prediction of sustained virological response to telaprevir-based triple therapy using viral response within 2 weeks" 2014 : 748935-, 2014
11 Tamai H, "Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation" 41 : 1137-1144, 2011
12 Roffi L, "Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis" 13 : 663-673, 2008
13 Di Marco V, "Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial" 47 : 484-491, 2007
14 Izumi N, "Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO- 3 studies" 49 : 941-953, 2014
15 Fried MW, "Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study" 58 : 1918-1929, 2013
16 Enomoto N, "Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection" 334 : 77-81, 1996
17 Tamai H, "Low-dose pegylated interferon- alpha2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load" 19 : 107-115, 2014
18 Tahata Y, "Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy" 88 : 1776-1784, 2016
19 Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of Hepatology, "Guidelines for the management of hepatitis c virus infection: first edition, May 2012, The Japan Society of Hepatology" 43 : 1-34, 2013
20 Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C" 41 : 1105-1109, 2009
21 Huang CF, "Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C" 201 : 751-759, 2010
22 Bruno S, "Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis" 51 : 388-397, 2010
23 Ogawa E, "Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure" 22 : 992-1001, 2015
24 Asahina Y, "Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection" 52 : 518-527, 2010
25 Ogawa E, "Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C" 30 : 1309-1316, 2015
26 Ogawa E, "Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection" 30 : 1759-1767, 2015
27 Simmonds P, "Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region" 74 (74): 2391-2399, 1993
28 Akuta N, "Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferonribavirin combination therapy" 48 : 372-380, 2005